Positron to Exhibit at the Society of Nuclear Medicine Annual Meeting
31 Maio 2011 - 10:00AM
Positron Corporation (OTCBB:POSC), a leading molecular imaging
company specializing in the field of nuclear cardiology, will be
exhibiting at the Society of Nuclear Medicine (SNM) Annual Meeting,
to be held in San Antonio, TX, June 4th through 8th, 2011.
Patrick G. Rooney, CEO of Positron, stated, "With the increased
interest in cardiac PET and the launch of the PosiRx system, our
participation at well-respected forums such as SNM is crucial to
meeting customers and creating market awareness. After
attendance at the American College of Cardiologists conference in
April and the more recent International Conference of
Non-Cardiovascular Imaging in Europe, we have seen a notable
increase in interest levels for both the cardiac PET and SPECT
pharmaceutical segments of our business. The exposure and
introductions gained from these industry conferences have yielded
opportunities that will advance our future growth."
Founded in 1954, the SNM is an international scientific and
professional organization that promotes the science, technology and
practical application of nuclear medicine. Its 16,000 members
are physicians, technologists and scientists that specialize in the
research and practice of nuclear medicine. The Society
maintains an active advocacy program which promotes and encourages
research for the advancement of nuclear medicine science, producing
a number of programs to help physicians and technologists remain
current on latest advancements. The Society also sponsors
educational programs for consumers to help them understand nuclear
medicine and the constructive role it can play in both diagnostic
and therapeutic therapies.
About Positron: Positron is a molecular imaging
company focused on Nuclear Cardiology. Positron Corporation, a
pioneer in molecular imaging for more than 25 years provides unique
solutions for the nuclear medicine community through the production
and distribution of proprietary PET molecular imaging systems and
PET & SPECT radiopharmaceutical products. More information
about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance and may involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Positron Corporation to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Our actual results may
differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including,
without limitation those set forth as "Risk Factors" in our filings
with the Securities and Exchange Commission.
For further information please contact Positron Corporation at
(317) 576-0183.
CONTACT: Positron Corporation
(317) 576-0183
Positron (PK) (USOTC:POSC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Positron (PK) (USOTC:POSC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024